J&J Sets Mid-2027 DePuy Spin as $20–22B Orthopedics Valuation Circulates; UK Clears Icotyde
JNJ sits 43% above its 52-week low of $184.66.
Summary
J&J plans to spin off its orthopedics unit, DePuy Synthes, around mid-2027, with private equity interest and market chatter putting the unit near $20–22 billion — no deal is finalized. Separately, UK regulators approved the oral psoriasis pill Icotyde for patients 12 and older weighing at least 40kg, based on four Phase 3 trials covering roughly 2,500 patients; the company also studies icotrokinra in other inflammatory diseases, with peak sales estimated near $5 billion. A third thread: talks on a key deal reached advanced agreement on terms and structure but collapsed at the last minute over a leadership dispute, per sources. The spin plan is the biggest structural item for a company this size — it would carve out a slower-growth orthopedics franchise and sharpen the focus on oncology, neuroscience and immunology, where TREMFYA and the oncology lineup are already growing. The Icotyde approval is a modest but real addition to the immunology pipeline, though the ~$5B peak-sales estimate is a multi-year proposition, not a near-term earnings driver. Watch for a formal Form 10 registration and spin-off timeline from the company; the collapsed talks carry no disclosed counterparty or terms, so their financial impact cannot be sized.
At the time of this announcement, JNJ was trading at $263.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $635.1B. The 52-week trading range was $184.66 to $281.07. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.